ExploreIterate

Monopteros

0 Followers

About

Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.

Photos

Add photos to showcase Monopteros’s culture

Values

Add Monopteros’s values

Insider experiences

Share your experience of working at Monopteros

Peter Keller
Chief Executive Officer
Collapse
Arthur DeCillis
Chief Medical Officer
Jon Lawson
Manufacturing
Norma Kim Ascroft
Regulatory Affairs
Sami Karaborni
Drug Development
Vijayapal Reddy
Non-Clinical Safety
Yun Gao
Chemistry

Add your teams to show how people work together at Monopteros

Add jobs to your org chart to show candidates who they’ll work with

Publish company announcements to get more exposure

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.